Nutex Health Inc. (NUTX) Form 10-Q — Aug 6, 2026
Nutex Health swung to Q2 2026 net income attributable of $65.8 million, or $9.38 per diluted share, versus a $17.7 million loss a year earlier, with Adjusted EBITDA rising to $90.0 million from $71.6 million as patient visits grew 9.6%. Revenue moved the other way: hospital division revenue fell 14.6% year over year to $201.9 million and total revenue came in at $210.8 million versus $244.0 million, meaning revenue per visit deteriorated even as volumes grew.
Key figures
- Eps
- $9.38 diluted / $9.58 basic (Q2 2026) vs. $(2.95) prior year; $15.87 diluted H1 2026
- Revenue
- $210.8M Q2 2026 ($427.2M H1 2026) vs. $244.0M Q2 2025 ($455.8M H1 2025)
- Net Income
- $96.3M total / $65.8M attributable to Nutex Health (Q2 2026) vs. $16.1M / $(17.7)M prior year
- Total Debt
- 39899000
- Revenue Yoy
- Total revenue -13.6% YoY in Q2 (computed); hospital division -14.6% as stated
- Total Assets
- 964629000
- Cash Position
- 205208000
- Shares Outstanding
- 6847973
- Footprint
- 27 hospital facilities in 12 states; ~1,037 full-time employees
- Cms Idr Admin Fee
- Reduced from $115 to $15 per party per dispute, effective June 11, 2026
- Idre Prepaid Fees
- $11.5M vs. $20.9M at Dec 31, 2025
- Earn Out Liability
- $4.9M vs. $8.3M at Dec 31, 2025 (under-construction hospital obligations)
- Patient Visits Q2
- 49962
- Adjusted EBITDA H1
- $147.5M vs. $144.4M prior year
- Adjusted EBITDA Q2
- $90.0M vs. $71.6M prior year
- Accounts Receivable
- $351.7M vs. $319.4M at Dec 31, 2025
- Hospital Revenue Q2
- $201.9M, -14.6% YoY
- Patient Visit Growth
- +9.6% YoY (same-hospital +6.3%)
- Operating Cash Flow H1
- $109.7M vs. $78.2M prior year
- Buyback Aug2025 Program
- Completed — $20.0M for 118,867 shares at $168.65 weighted average (H1 2026)
- Buyback Mar2026 Program
- $5.2M for 46,524 shares at $110.88 weighted average (H1 2026); ~$19.8M remaining
- Noncontrolling Interests
- $113.0M equity; $30.5M of Q2 net income attributable to NCI
- Accrued Arbitration Expenses
- $49.7M
- Change In Estimate eps Impact
- $3.64 basic / $3.56 diluted per share
- Settlement Share Retirements H1
- 147,352 shares retired at $25.3M aggregate value; 86,836 shares at $15.6M in Q2
- Change In Estimate expense Reduction
- $52.3M reduction to contract services expense (3 and 6 months)
- Change In Estimate net Income Benefit
- $43.0M to net income; $25.0M to net income attributable to Nutex
Price after filing
1 day: -0.3%7 days: +18.4%30 days: +22.5%
Close on the filing date to close N calendar days later (from $157.80). Historical, not a forecast.
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.